These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Cervantes-Gomez F; Chen LS; Orlowski RZ; Gandhi V Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S317-29. PubMed ID: 23988451 [TBL] [Abstract][Full Text] [Related]
5. Ribosomal Biogenesis and Translational Flux Inhibition by the Selective Inhibitor of Nuclear Export (SINE) XPO1 Antagonist KPT-185. Tabe Y; Kojima K; Yamamoto S; Sekihara K; Matsushita H; Davis RE; Wang Z; Ma W; Ishizawa J; Kazuno S; Kauffman M; Shacham S; Fujimura T; Ueno T; Miida T; Andreeff M PLoS One; 2015; 10(9):e0137210. PubMed ID: 26340096 [TBL] [Abstract][Full Text] [Related]
6. Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma. Yang Q; Chen LS; Neelapu SS; Gandhi V Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2(0 2):S355-62. PubMed ID: 24290221 [TBL] [Abstract][Full Text] [Related]
7. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Lin YW; Beharry ZM; Hill EG; Song JH; Wang W; Xia Z; Zhang Z; Aplan PD; Aster JC; Smith CD; Kraft AS Blood; 2010 Jan; 115(4):824-33. PubMed ID: 19965690 [TBL] [Abstract][Full Text] [Related]
8. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets. Saurabh K; Scherzer MT; Shah PP; Mims AS; Lockwood WW; Kraft AS; Beverly LJ Oncotarget; 2014 Sep; 5(18):8503-14. PubMed ID: 25238262 [TBL] [Abstract][Full Text] [Related]
9. PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells. Siu A; Virtanen C; Jongstra J Oncotarget; 2011 Dec; 2(12):1134-44. PubMed ID: 22193779 [TBL] [Abstract][Full Text] [Related]
10. The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms. Natarajan K; Bhullar J; Shukla S; Burcu M; Chen ZS; Ambudkar SV; Baer MR Biochem Pharmacol; 2013 Feb; 85(4):514-24. PubMed ID: 23261525 [TBL] [Abstract][Full Text] [Related]
12. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Asano J; Nakano A; Oda A; Amou H; Hiasa M; Takeuchi K; Miki H; Nakamura S; Harada T; Fujii S; Kagawa K; Endo I; Yata K; Sakai A; Ozaki S; Matsumoto T; Abe M Leukemia; 2011 Jul; 25(7):1182-8. PubMed ID: 21475253 [TBL] [Abstract][Full Text] [Related]
13. PIM kinases as therapeutic targets against advanced melanoma. Shannan B; Watters A; Chen Q; Mollin S; Dörr M; Meggers E; Xu X; Gimotty PA; Perego M; Li L; Benci J; Krepler C; Brafford P; Zhang J; Wei Z; Zhang G; Liu Q; Yin X; Nathanson KL; Herlyn M; Vultur A Oncotarget; 2016 Aug; 7(34):54897-54912. PubMed ID: 27448973 [TBL] [Abstract][Full Text] [Related]
14. A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas. Foulks JM; Carpenter KJ; Luo B; Xu Y; Senina A; Nix R; Chan A; Clifford A; Wilkes M; Vollmer D; Brenning B; Merx S; Lai S; McCullar MV; Ho KK; Albertson DJ; Call LT; Bearss JJ; Tripp S; Liu T; Stephens BJ; Mollard A; Warner SL; Bearss DJ; Kanner SB Neoplasia; 2014 May; 16(5):403-12. PubMed ID: 24953177 [TBL] [Abstract][Full Text] [Related]
15. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1). Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821 [TBL] [Abstract][Full Text] [Related]
16. Biochemical changes of salivary gland adenoid cystic carcinoma cells induced by SGI-1776. Hou X; Yu Y; Feng J; Wang J; Zheng C; Ling Z; Ge M; Zhu X Exp Cell Res; 2017 Mar; 352(2):403-411. PubMed ID: 28228352 [TBL] [Abstract][Full Text] [Related]
17. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma. Mahalingam D; Espitia CM; Medina EC; Esquivel JA; Kelly KR; Bearss D; Choy G; Taverna P; Carew JS; Giles FJ; Nawrocki ST Br J Cancer; 2011 Nov; 105(10):1563-73. PubMed ID: 22015557 [TBL] [Abstract][Full Text] [Related]
18. The novel anti-adipogenic effect and mechanisms of action of SGI-1776, a Pim-specific inhibitor, in 3T3-L1 adipocytes. Park YK; Hong VS; Lee TY; Lee J; Choi JS; Park DS; Park GY; Jang BC Int J Mol Med; 2016 Jan; 37(1):157-64. PubMed ID: 26719859 [TBL] [Abstract][Full Text] [Related]
19. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies]. Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773 [TBL] [Abstract][Full Text] [Related]
20. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Prasad A; Park IW; Allen H; Zhang X; Reddy MV; Boominathan R; Reddy EP; Groopman JE Oncogene; 2009 Mar; 28(12):1518-28. PubMed ID: 19198627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]